P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN®-multiantigen vaccine: high responder rate and considerable breadth of immunological response.
about
P18-12 LB. Phase I clinical trial with a new recombinant MVA-BN®-multiantigen vaccine: high responder rate and considerable breadth of immunological response.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
P18-12 LB. Phase I clinical tr ...... dth of immunological response.
@en
P18-12 LB. Phase I clinical tr ...... dth of immunological response.
@nl
type
label
P18-12 LB. Phase I clinical tr ...... dth of immunological response.
@en
P18-12 LB. Phase I clinical tr ...... dth of immunological response.
@nl
prefLabel
P18-12 LB. Phase I clinical tr ...... dth of immunological response.
@en
P18-12 LB. Phase I clinical tr ...... dth of immunological response.
@nl
P2093
P1433
P1476
P18-12 LB. Phase I clinical tr ...... dth of immunological response.
@en
P2093
A Ludvigsen
R Steigerwald
P2888
P304
P356
10.1186/1742-4690-6-S3-P411
P433
P50
P577
2009-10-22T00:00:00Z
P5875
P6179
1033489205